Pacira Pharmaceuticals posted results from its Phase IV study of Exparel in laparoscopic colectomy. The study, known as IMPROVE, represents a series of open-label prospective Phase 4 trials to assess the differences in postsurgical opioid use and health economic outcomes between patients receiving  Exparel (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control. Exparel is indicated for ...